A detailed history of Dana Investment Advisors, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Dana Investment Advisors, Inc. holds 10,154 shares of GILD stock, worth $894,364. This represents 0.02% of its overall portfolio holdings.

Number of Shares
10,154
Previous 10,154 -0.0%
Holding current value
$894,364
Previous $696,000 -0.0%
% of portfolio
0.02%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$63.15 - $72.88 $1,957 - $2,259
31 Added 0.31%
10,154 $696,000
Q1 2024

May 15, 2024

BUY
$71.58 - $87.29 $7,873 - $9,601
110 Added 1.1%
10,123 $741,000
Q4 2023

Feb 07, 2024

BUY
$73.27 - $83.09 $58,249 - $66,056
795 Added 8.62%
10,013 $811,000
Q3 2023

Nov 15, 2023

BUY
$73.94 - $80.67 $43,328 - $47,272
586 Added 6.79%
9,218 $690,000
Q1 2023

May 15, 2023

BUY
$77.31 - $88.08 $3,710 - $4,227
48 Added 0.56%
8,632 $716,000
Q4 2022

Feb 13, 2023

BUY
$62.32 - $89.47 $28,044 - $40,261
450 Added 5.53%
8,584 $736,000
Q3 2022

Nov 15, 2022

SELL
$59.54 - $68.01 $4,525 - $5,168
-76 Reduced 0.93%
8,134 $502,000
Q2 2022

Aug 15, 2022

BUY
$57.72 - $65.01 $473,881 - $533,732
8,210 New
8,210 $507,000
Q3 2019

Nov 12, 2019

SELL
$62.51 - $69.0 $200,594 - $221,421
-3,209 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$61.87 - $69.38 $198,540 - $222,640
3,209 New
3,209 $217,000
Q2 2018

Aug 01, 2018

SELL
$64.88 - $75.68 $1.75 Million - $2.04 Million
-26,924 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$72.84 - $88.8 $5,317 - $6,482
73 Added 0.27%
26,924 $2.03 Million
Q4 2017

Feb 13, 2018

SELL
$71.15 - $83.52 $101,602 - $119,266
-1,428 Reduced 5.05%
26,851 $0
Q3 2017

Nov 15, 2017

BUY
$72.11 - $85.47 $2.04 Million - $2.42 Million
28,279
28,279 $2.29 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Dana Investment Advisors, Inc. Portfolio

Follow Dana Investment Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dana Investment Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Dana Investment Advisors, Inc. with notifications on news.